[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635218":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":31,"locations":20,"responsibleParty":37,"collaborators":20,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":20,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":20,"enrollmentInfo":49,"targetDuration":20,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":69,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":20},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Sebutape sampling and analysis","EXPERIMENTAL","All participants will undergo non-invasive sebum sampling using Sebutape. Samples will be analyzed for metabolomic and lipidomic profiles using LC-MS\u002FMS, and microbiome profiling will be performed using 16S rRNA sequencing. Subgroups include healthy individuals, patients with skin diseases, individuals undergoing dermatological treatments or using skincare products, and a subset of healthy participants receiving short-term topical antibiotic intervention.",[13,14],"Other: Sebutape sampling","Drug: Bacitracin\u002FPolymyxin B\u002FNeomycin ointment (Yentuogin ointment)",[16,21],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"Sebutape sampling","Non-invasive sebum sampling using Sebutape patches. Each participant will undergo standardized sampling procedures, with one patch used for metabolomics\u002Flipidomics analysis and another for microbiome profiling. Samples will be stored at -80 °C for subsequent LC-MS\u002FMS and 16S rRNA sequencing.",[9],null,{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":20},"DRUG","Bacitracin\u002FPolymyxin B\u002FNeomycin ointment (Yentuogin ointment)","Short-term topical antibiotic intervention using Yentuogin ointment containing Bacitracin, Polymyxin B, and Neomycin. Healthy participants will apply the ointment 1-2 times daily for up to 3 days. Sebutape samples will be collected before and after intervention to assess changes in sebum composition and skin microbiome.",[9],[27],{"name":28,"affiliation":29,"role":30},"Ching_Hua Kuo","National Taiwan University","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":20,"email":36},"Ya-Chu Kuo, PhD","CONTACT","+886-2-3366-8766","iris890402@gmail.com",{"type":38,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100635218","sebum-metabolomics-and-lipidomics-for-clinical-applications-100635218",false,"NCT07549828","Sebum Metabolomics and Lipidomics for Clinical Applications","Development of a Sample Collection Protocol and a Metabolomics\u002FLipidomics Analytical Strategy for Investigating Sebum and Its Clinical Applications","A. Healthy Participants\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be in good health and suitable for participation.\n* No diagnosed skin diseases or chronic systemic diseases.\n* No use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Presence of acute or chronic skin diseases, or chronic systemic diseases.\n* Use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nB. Participants with Skin Diseases or Specific Skin Conditions\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be suitable for participation.\n* Diagnosed by a physician or clinically assessed as having one of the following:\n\n  * Acne\n  * Atopic dermatitis\n  * Seborrheic dermatitis\n  * Psoriasis\n  * Other common skin diseases\n  * Specific skin conditions (e.g., postmenopausal or aging-related skin changes)\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Severe disease that may compromise skin integrity or pose a risk to participant safety.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nC. Participants Receiving Dermatological Treatments or Using Skincare Products\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be suitable for participation.\n* Participants who, based on clinical needs or daily routines, are currently using or are expected to use or receive any of the following:\n\n  * Physician-prescribed topical dermatological medications\n  * Physician-prescribed systemic therapies (oral or injectable)\n  * Routine use of general skincare products\n  * Physician-directed non-invasive dermatological treatments\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Severe disease that may compromise skin integrity or pose a risk to participant safety.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nD. Healthy Participants Undergoing Short-term Antibiotic Intervention\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity.\n* Assessed by the investigator to be healthy, with skin condition suitable for the intervention used in this study.\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Known allergy or adverse reactions to the study intervention drug (topical antibiotic ointment containing bacitracin, polymyxin B, and neomycin).\n* Presence of visible skin disease, wounds, infection, inflammation, or other abnormal skin conditions at the sampling site.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.",true,"ALL","20 Years",{"count":50,"type":51},200,"ESTIMATED","INTERVENTIONAL",[54],"NA","This study aims to develop a standardized workflow for sebum sampling and metabolomics\u002Flipidomics analysis using Sebutape. A total of 200 participants will be recruited, including healthy individuals, patients with skin diseases, individuals undergoing dermatological treatments or using skincare products, and a subset of healthy participants receiving short-term topical antibiotic intervention. The study will investigate sebum composition, skin microbiome profiles, and their interactions under different conditions to explore potential biomarkers and clinical applications.",[57,58,59,60,61],"Acne","Atopic Dermatitis","Seborrheic Dermatitis","Psoriasis","Healthy Subjects (HS)",[63,64,65,66,67,68],"Sebum","Lipidomics","Metabolomics","Skin microbiome","Sebutape","LC-MS\u002FMS","NOT_YET_RECRUITING","2026-04-17",{"date":72,"type":73},"2026-04-24","ACTUAL",{"date":75,"type":51},"2026-04-01",{"date":77,"type":51},"2029-03-31",{"name":5,"class":6}]